Post on 06-Mar-2018
Use of quantitative real time PCR to assess gene transcripts associated with
antibody-mediated rejection of kidney transplants
Dominy, KMa, Roufosse, Cab, de Kort, Ha, Willicombe, Mc, Brookes, Pd, Behmoaras, JVa,
Petretto, EGe, Galliford, Jc, Choi, Pc, Taube, Dc, Cook, HTa,b, Mclean, AGc
a Centre for Complement and Inflammation Research, Division of Immunology and Inflammation, Department of Medicine, Imperial College, London, UKb Dept Cellular Pathology, Hammersmith Hospital, London, UKc Imperial College Kidney and Transplant Institute, Hammersmith Hospital, London, UKd Histocompatibility and Immunogenetics Laboratory, Imperial College Healthcare NHS Trust, London, UK e Medical Research Council Clinical Sciences Centre, Faculty of Medicine, Imperial College, London, UK
Corresponding author: Dr Adam Mclean adam.mclean@imperial.nhs.uk
Word Count
Abstract: 205
Text: 3078
Key words:
Antibody-mediated rejection (AbMR); Endothelial associated transcripts (ENDATs), Kidney
transplantation; Natural Killer (NK) cells; quantitative real time PCR (qRT-PCR);
1
1
2
3
4
5
6789
1011121314
15
16
17
18
19
20
21
22
23
Statement of author contributions
KD carried out experiments and data analysis. HdK, MW and PB identified suitable patients
and obtained DSA data. JG, PC and AM collected biopsy material. EP performed data
analysis. CR and HdK assessed histology. AM, JB, HTC and CR designed the study and
obtained funding. All authors were involved in writing the paper and had final approval of
the submitted and published versions.
FundingWe are grateful for support from the NIHR Biomedical Research Centre funding scheme. The
authors would like to acknowledge the European Renal Association—European Dialysis and
Transplant Association (ERA/EDTA) for the awarded long-term fellowship.
Conflict of interestNone
2
24
25
26
27
28
29
3031
32
33
343536
List of abbreviations
Antibody mediated rejection (AbMR), Cadherin 5 (CDH5), complementary DNA (cDNA),
Threshold Cycle Number (Ct), chemokine (C-X3-C motif) receptor 1 (CX3CR1), Duffy Coat
Antigen Receptor (DARC),Donor specific antibody (DSA), Endothelial associated transcripts
(ENDAT), Fibroblast Growth Factor binding Protein 2 (FGFBP2), Glomerulitis (G), Granulysin
(GNLY), diabetic glomerulopathy (GP), Hypoxanthine phosphoribosyltransferase 1 (HPRT1),
Killer Cell Lectin-like receptor subfamily F, Member 1 (KLRF1), Mean Fluorescent Intensity
(MFI), Microcirculation inflammation (MI), v-myb myeloblastosis viral oncogene homolog
(avian) like 1 (MLYB1), Natural killer (NK), Platelet / Endothelial cell Adhesion Molecule 1
(PECAM1), Peritubular Capillaritis (ptc), Peritubular capillary basement membrane
multilayering (PTCBML) ,quantitative real time PCR (qRT-PCR), Receiver operating
characteristic (ROC), SH2 domain containing 1B (SH2D1b (EAT2)), Sex determining region Y
box 7 (SOX7), T-Cell mediated rejection (TCMR), Transplant glomerulopathy (TG), von
Willebrand Factor (vWF)
3
37
38
39
40
41
42
43
44
45
46
47
48
49
50
1
Abstract
Introduction
Microarray studies have shown elevated transcript levels of endothelial and natural killer
(NK) cell associated genes during antibody mediated rejection (AbMR) of the renal allograft.
This study aimed to assess the use of quantitative real-time PCR (qRT-PCR) as an alternative
to microarray analysis on a subset of these elevated genes.
Methods
39 renal transplant biopsies from patients with de novo donor-specific antibodies and 18
one year surveillance biopsies with no histological evidence of rejection were analysed for
expression of 11 genes previously identified as elevated in AbMR.
Results
Expression levels of NK markers were correlated to microcirculation inflammation (MI) and
graft outcomes to a greater extent than endothelial markers. Creating a predictive model
reduced the number of gene transcripts to be assessed to 2, SH2D1b and MYBL1, resulting
in 66.7% sensitivity and 89.7% specificity for graft loss.
Discussion
This work demonstrates that elevated gene expression levels, proposed to be associated
with AbMR, can be detected by established qRT-PCR technology, making transition to the
clinical setting feasible. Transcript analysis provides additional diagnostic information to the
classification schema for AbMR diagnosis but it remains to be determined whether
4
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
significant numbers of centres will validate transcript analysis in their labs and put such
analysis into clinical use.
5
22
23
Introduction
Antibody-mediated rejection (AbMR) is an important cause of graft injury (1) and a major
source of graft failure (2). Diagnosis of AbMR is based on criteria in the Banff classification of
renal allograft pathology (3, 4), requiring presence of donor-specific antibody (DSA) in the
circulation, a renal biopsy with defined histological features, and evidence of current /
recent antibody interaction with the vascular endothelium, such as positive C4d staining (5).
Hyperacute AbMR has been virtually eliminated because of improved cross-matching prior
to transplantation (1). Acute and chronic AbMR can nevertheless develop because of the
appearance of de novo DSA against the graft post-transplantation.
Recent microarray analyses carried out on renal biopsies have identified endothelial
associated gene transcripts (ENDATs) (6) and NK cell associated transcripts (7), which are
elevated in cases of AbMR. The identification of these high transcript levels in some cases
with histological evidence of AbMR and the presence of DSA but no staining for C4d, has
helped confirm the existence of C4d-negative AbMR (8-10). It was demonstrated by Sis et al
(6) that although C4d staining is highly specific for AbMR, it lacks sensitivity. A proposal has
been made that analysis of expression levels of endothelial and/or natural killer (NK) cell
transcripts could complement C4d as a marker of endothelial injury by the antibody in these
cases (11-14).
The most recent Banff update recognises C4d-negative AbMR, which is observed particularly
in presensitised patients, but also in patients with de novo DSA (9). An alternative to the
presence of C4d is a microcirculation inflammation (MI) score ≥2, comprising the sum of
peritubular capillaritis (ptc) and glomerulitis (g) scores, but meaningful cut-off levels and
6
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
reproducibility for ptc and g scores have proved difficult issues to fully resolve. Alternatively,
increased gene expression could be indicative of endothelial injury.
Microarray analysis is advantageous because a small sample amount can be used to analyse
many gene transcripts simultaneously. However, this method is hybridisation based and
previous studies have demonstrated that quantitative real time PCR (qRT-PCR) yields
comparable results but has a greater sensitivity for individual gene expression levels due to
its increased dynamic range (15).
qRT-PCR is emerging as a valuable technique in the clinical diagnostic setting and is currently
used in a variety of different contexts including detection of viral load, therapy monitoring
and for diagnosis and detection of disease-specific prognostic markers in leukaemia patients
(16).
We hypothesised that measurement of gene expression by qRT-PCR, of the most
significantly elevated transcripts defined by microarray analysis, would correlate with the
histological features of AbMR and potentially provide sufficient information to be of
importance in diagnosis of AbMR and prediction of graft loss.
7
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
Results
De novo DSA biopsies for transcript analysis
For the purposes of this study, biopsies collected between February 2010 and August 2012
from patients with de novo DSA (developed at any time post-transplant) were examined.
127 biopsies from 96 patients were included in the study (mean number of biopsies =1.35
(±0.95) per patient).
15 biopsies were excluded because they were either ABO incompatible (n=13) or
simultaneous pancreas kidney transplants (n=2). From the remaining 112, 53 had sufficient
RNA for analysis (>200ng), of which 39 biopsies from 30 patients passed qRT-PCR quality
control checks and were used to assess transcript levels. Average time of biopsy post-
transplant was 2.02 years (±2.04). One year surveillance biopsies (n=18) were also assayed
for comparison.
Table 1 details histological findings. Further patient information was collected from medical
notes (Table S1).
RNA yield and quality
From the 57 biopsies (39 de novo DSA and 18 surveillance), mean RNA yield was
1328.56ng/biopsy (±962.34). Mean weight of biopsy was 1.94mg (±1.14). There was a
significant correlation between the weight of the biopsy and the RNA yield (p=0.00017,
paired T-Test). Mean RNA yield per mg of biopsy was 889.27 ng/mg (±903.8).
8
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
Biopsies were performed by 3 individuals who yielded significantly different amounts of RNA
(p<0.001). However, when ng RNA per mg of biopsy was calculated, there was no significant
difference in RNA yield between different clinicians (p=0.44, Kruskal-Wallis test).
RNA quality was assessed in a selection of 15 samples. RNA integrity number (17) ranged
from 1.0 to 8.8 but all samples amplified in qRT-PCR analysis.
Transcript expression: correlation with MI score
All 57 biopsies were scored according to the Banff criteria (4), an MI score calculated as
previously described (8, 18) and then grouped into surveillance, MI score of ≤1, and MI
score >1. Expression levels of 11 genes (5 ENDATs and 6 NKs) (Table S2) were determined by
qRT-PCR.
Expression levels were compared between the two MI score groups (≤1 and >1) and the
surveillance samples (Figure 1). Mann-Whitney U tests (Table 2) demonstrated a significant
difference between expression levels of the two MI groups for 4 of the 11 genes (FGFBP1
p=0.007, GNLY p=0.001, MYBL1 p=0.010, SH2D1b p=0.004), all of which were NK cell
associated transcripts.
Transcript analysis has been key to the definition of C4d negative AbMR, therefore a subset
analysis of biopsies that were DSA positive but C4d negative (n=30) was performed to
determine if association between transcript levels and MI remains (Table 2). FGFBP1
(p=0.031), GNLY ( p=0.001), MYBL ( p=0.003), and SH2D1b (p=0.012) remained significantly
associated with MI and DARC (p=0.01) additionally achieved significance.
The presence of donor specific antibodies is a key factor in diagnosis of AbMR. We sought to
compare transcript expression in samples with single or multiple HLA antibodies and across
9
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
different HLA classes (Table S3). In biopsies from patients with more than one DSA, there
was significant elevation of FGFBP2 (p=0.006), GNLY (p=0.003), MYBL (p=0.046) and SH2D1b
(p=0.006). No difference was seen between HLA classes.
Acute and chronic AbMR are known to be clinically different and therefore the 39 de novo
DSA samples were separated according to AbMR status (Figure S1). Formal analysis
comparing acute and chronic AbMR has not been carried out due to the small sample size,
however there is an apparent trend that the ENDATs are elevated in only chronic cases
whereas NK transcripts are elevated in both acute and chronic cases.
In light of the association between MI and NK cells, further genes were selected to
represent T-cell and macrophage mRNA levels. This was to determine whether the elevated
transcript level reflected an association with antibodies or simply inflammation. Six out of 7
T-cell and macrophage transcripts showed no elevation in the MI positive group. CXCL11 did
show association with MI in both the de novo DSA group (p=0.041) and the combined de
novo DSA and surveillance group (p=0.007). However, given that the majority of
inflammation transcripts did not associate with MI, we do not consider elevated NK
transcript levels to indicate just inflammation.
Building a predictive model
To determine if transcript analysis could predict MI group, binary logistic regression analysis
was performed. An initial univariate analysis was performed on each individual transcript
and other pre-existing factors. The outcome measure was MI group. When examining all
samples, GNLY, MYBL1 and SH2D1b showed significant correlation with MI score (p= 0.002,
0.003, 0.001 respectively) (Table 3a). DARC (p=0.05) and time from transplant to biopsy
10
104
105
106
107
108
109
110
111
112113
114
115
116
117
118
119
120
121
122
123
124
125
126
(p=0.003) were also significantly correlated with MI score but significance was lost in the
subgroup of de novo DSA samples (p=0.176 and 0.313 respectively)(Table 3Table 3b).
To create a predictive model, parameters with suggestive significance (p<0.10) were
included in a multivariate binary logistic regression. The generated model contained two
parameters – SH2D1b and MYBL1.
Graft Survival
During follow-up (maximum 4 years 2 months), 10/30 grafts were lost from the de novo DSA
group and 0/18 from the surveillance group. The predictive model, based on SH2D1b and
MYBL1, was used to assign each patient to a low or high risk group and Kaplan Meier
survival curves (Figure 2) were generated. When all patients were assessed there was an
association between risk group and graft loss (p=0.008). Within the de novo DSA group the
association increased (p<0.001). The 3 graft losses from the low risk group were in patients
where the biopsy had extensive scarring.
11
128
129
130
131
132
133
134
135
136
137
138
139
140
Discussion
In this study, we sought to assess whether we could focus gene expression analysis in AbMR
on the most elevated transcripts from previous microarray studies. We have used qRT-PCR
to demonstrate increased expression of genes in biopsies with high MI scores, suggesting
that gene expression correlates with AbMR and subsequently graft loss. The association of
NK transcript expression with graft loss in this study is a novel finding.
Genes without elevated expression in high MI score samples could genuinely lack a
correlation or the sample size is too small to detect an effect. The differing technology may
influence results, although factors such as immune suppression regimes and time since
transplant will not be matched to previous studies. We have examined early and late
biopsies whereas previous studies have been focussed on either late or early biopsies (6).
The differing transcript levels in the chronic and acute AbMR groups warrants further
investigation and could be masking association of ENDAT levels and AbMR. The conclusion
of this study should therefore be seen as preliminary and will require confirmation with a
larger sample size of patients and longer follow-up.
Increasing the number of transcripts assessed does not necessarily provide additional
information, as indicated by our predictive model which contained just 2 genes. With an
ever changing list of top hits from microarray analysis, we would hypothesise that a small
selection of genes should be sufficient to represent expression differences in AbMR patients,
without the need for complete microarray analysis. However, we have not assessed the full
range of possible diagnoses and inclusion of a wider range may bring up a different set of
top transcripts.
12
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
In some circumstances, biopsy material can be insufficient for diagnostic purposes. The
three graft losses in the low risk group were from patients with extensive scarring and we
hypothesise that transcript levels might not have any diagnostic value in these
circumstances. A disadvantage of transcript analysis is the destruction of the structural
integrity of the specimen; histological assessment can be made on very small non-scarred
areas in an otherwise scarred biopsy, but this scarring may mask any elevated mRNA
transcripts. Future use of laser-microdissection of non-scarred areas from formalin-fixed and
paraffin embedded tissues may provide a solution to this problem.
The study also assessed the feasibility of obtaining adequate samples for mRNA analysis in
the routine transplant biopsy clinic. It appears that in order to obtain consistently good
yields of RNA, sufficient for qRT-PCR analysis, a whole additional biopsy core would be
needed. The diagnostic benefit of transcript analysis must be weighed up against the
potential risk to the patient of taking an additional core.
In contrast to other work (6), this study has found little evidence that ENDATs are associated
with AbMR. Other, larger cohorts have included ENDATs in microarray analysis, to improve
stratification for graft loss within the first year post transplant (19). This could be explained
by the larger sample size in these studies or the use of mainly chronic AbMR samples rather
than both active and chronic active AbMR cases.
The diagnostic criteria of AbMR have recently been reassessed to recognise subclinical
AbMR (8, 20, 21), and C4d-negative AbMR (5), both of which can lead to late allograft loss.
Features predicting risk of progression to chronic rejection and graft loss in patients with
DSA are still being defined. Potential candidates include DSA levels, type and ability to fix
13
163
164
165
166
167
168
169
170
171
172
173
174
175
176177
178
179
180
181
182
183
184
185
complement, histological features, C4d staining and molecular findings (22). NK cells may
participate in the progression to chronic rejection independent of complement activation
through antibody-dependent cell-mediated cytotoxicity, and NK cell related transcripts
could therefore identify cases at risk (7).
NK transcript levels have the potential to enhance recognition of cases of AbMR by joining
the diagnostic criteria, and also to enhance accurate prediction of outcome. In particular
because no reliable immunohistochemical method has yet been found to identify NK cells in
the graft or to document endothelial activation, mRNA analysis may have an important role
to play.
New therapies are being developed for the treatment of AbMR and demonstrate evidence
of improved outcome (23). Early detection and treatment of subclinical rejection has
demonstrated beneficial effects (24), although prospective studies are required to
determine if current early treatment methods result in improved kidney function and graft
survival over time.
Biopsies are required in order to diagnose AbMR, but if rejection is sub-clinical, this requires
a protocol biopsy or biopsy for another clinical indication. Material which is less invasive to
collect, such as blood or urine, could be a target for the future. Hayde et al (25) have
analysed whole blood gene expression profiles of AbMR patients and found increased gene
transcripts associated with cytotoxic T cells and macrophages, indicating that it is possible to
detect transcript level changes in alternative material.. Another area of interest may be
microRNA expression patterns, both in blood and biopsy material (26).
14
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
The “gold standard” for diagnosis of AbMR has not been established and there is variability
in histological scoring, making validation of new methods more difficult. Work such as that
presented here provides additional support for the role of transcript analysis in AbMR
diagnostics, by illustrating the feasibility of sample collection for qRT-PCR and by confirming
elevated NK transcript levels in AbMR. It remains to be determined if this approach, along
with DSA levels, type and ability to fix complement, histological features and C4d staining,
will provide more accurate and timely information compared to that which is already
included in the Banff schema.
15
208
209
210
211
212
213
214
215
216
Materials and methods
Patients and sample collection
All patients gave written, signed consent for the use of biopsy material surplus to clinical
diagnostic requirements to be used for research, and the study was undertaken with
approval from the local institutional review board (Local Research Ethics Committee
reference LREC 08/H0707/14).
From February 2010, renal transplant biopsies in our institute (whether indication or
surveillance) included a portion preserved in RNAlater (Life Technologies, Paisley, UK), when
sufficient material was available. Renal biopsy cores were obtained under ultrasound
guidance by 18 gauge spring-loaded needle. The sample in RNALater was retained for
diagnostic purposes, and if necessary, retrieved and formalin-fixed for diagnosis. Otherwise,
the sample was used directly for RNA extraction.
Histopathology
All biopsies were graded using Banff 2007 criteria (4). C4d staining was carried out by
immunoperoxidase on paraffin sections, using polyclonal rabbit anti-C4d antibody at 1/40
(Oxford Biosystems, BI-RC4D). The slides were subjected to microwave antigen retrieval (in
citrate buffer pH6), then placed on the Biogenex i6000 autostainer. The Biogenex Non-Biotin
detection kit was employed. C4d staining in peritubular capillaries was classified as
negative/minimal (C4d0/C4d1 <1% and 1-10% of peritubular capillaries respectively), focal
(C4d2, 11-50% of peritubular capillaries) or diffuse (C4d3, >50% of peritubular capillaries)(4).
16
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
Patients of this study were selected for DSA positivity, so acute AbMR was defined by the
presence of MI (glomerulitis and/or peritubular capillaritis and/or thrombotic
microangiopathy) with C4d (focal or diffuse). C4d-negatice acute AbMR was defined as MI,
and negative or minimal C4d staining. Chronic AbMR was defined as the presence of
transplant glomerulopathy (TG) and/or significant multilayering of peritubular capillary
basement membranes (PTCBML), and/or chronic allograft arteriopathy, with C4d (focal or
diffuse). C4d-negative chronic AbMR was defined as the same features but no C4d staining.
TG was defined by the presence of double contours on light microscopy, with only small
amounts of electron dense deposits on electron microscopy, and no clinical features of
thrombotic microangiopathy or hepatitis C infection. Significant PTCBML was defined as ≥1
ptc with ≥7 layers or ≥3 ptc with ≥5 layers of basement membrane (27).
Anti-HLA antibody screening
DSA were assessed using LABScreen® mixed beads (One lambda, Inc., Canoga Park, CA, USA)
and if positive, the anti-HLA antibody specificity was identified using LABScreen® single
antigen beads. Before transplantation all donor-recipient pairs had a negative T- and B cell
complement-dependent cytotoxicity crossmatch and a negative T cell flow cytometric
crossmatch, defined as mean fluorescence intensity (MFI) <300 pre-transplantation. Post-
transplantation an MFI >500 was considered DSA positive or MFI 300-500, in two
independent serum samples. Patients were typed for HLA –A, –B, –Cw, –DR and –DQ
antigens.
RNA extraction and reverse transcription
RNA extraction was performed using the RNAqueous micro kit (Ambion, Paisley, UK) and
quantified with a NanoDrop 1000 Spectrophotometer (LabTech, East Sussex, UK). Up to 1µg
17
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
RNA was converted to complementary DNA (cDNA) using an iScript select kit (Bio-Rad,
Hemel Hempstead, UK) with random hexamer priming. Sample quality was assessed using a
2100 Bioanalyzer and Agilent RNA 6000 Nano chip (Agilent Technologies, Berkshire, UK).
Quantitative real time PCR
Quantitative real time PCR was carried out using an Applied Biosystems 7500 real time qPCR
machine. 10ng cDNA was used in a SYBR green assay (Agilent Technologies, Berkshire, UK)
with gene specific primers spanning an intron (Table S2). Top gene hits from microarray
studies (6, 7, 9) were selected for analysis. Reactions were performed in triplicate at 95°C
for 10 min, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 min. A threshold
cycle (CT) was recorded in the exponential phase of amplification and melt curves were
created to confirm primer specificity (15 seconds 95°C, 1 minute 60°C increasing at
0.05°C/second to 95°C for 15 seconds). HPRT1 was the reference gene and results were
measured relative to Stratagene QPCR Reference RNA (Agilent Technologies, Berkshire, UK)
using the ∆∆CT method (28).
Graft Survival
Graft failure was defined as resuming dialysis and censored for patient death and short
follow up times. Graft survival was calculated by the Kaplan-Meier method and the log rank
test was applied. Survival time was measured from time of biopsy to prevent bias from older
transplants. For multiple biopsies from the same patient, the first biopsy after DSA detection
was used for survival analysis. Graft survival was assessed as of April 2014, resulting in a
follow up time between 20 and 50 months.
18
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
Data Analysis
Correlation between biopsy weight and RNA yield was tested with a paired T-Test and
expression data was normalised onto the same scale for each gene by calculating a Z-score
(Z= (X-mean )/Standard deviation) using Microsoft Excel. Further statistical calculations were
carried out using IBM SPSS statistics 19 software package. Kruskal-Wallis tests were applied
to comparisons of RNA yield from different clinicians. Mann-Whitney U tests were applied
to the data to detect differences in gene expression between two MI groups. Univariate
logistic regression was applied to individual factors. P-values <0.05 were considered to be
statistically significant. Multivariate logistic regression with a forward stepwise method was
applied to obtain a predictive model.
19
283
284
285
286
287
288
289
290
291
292
293294
References
1. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18 (4): 1046.
2. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90 (1): 68.
3. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55 (2): 713.
4. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8 (4): 753.
5. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14 (2): 272.
6. Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9 (10): 2312.
7. Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10 (8): 1812.
8. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009; 9 (11): 2561.
9. Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15 (1): 42.
10. Haas M. C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival. Clin Nephrol 2011; 75 (4): 271.
11. de Kort H, Willicombe M, Brookes P, et al. Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Am J Transplant 2013; 13 (2): 485.
12. Haas M. Pathology of C4d-negative antibody-mediated rejection in renal allografts. Curr Opin Organ Transplant 2013; 18 (3): 319.
13. Sis B. Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection. Hum Immunol 2012; 73 (12):
20
295
296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333
1218.14. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in
early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11 (1): 56.
15. Allanach K, Mengel M, Einecke G, et al. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant 2008; 8 (5): 1006.
16. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond) 2005; 109 (4): 365.
17. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006; 7: 3.
18. Sis B, Jhangri GS, Riopel J, et al. A New Diagnostic Algorithm for Antibody-Mediated Microcirculation Inflammation in Kidney Transplants. Am J Transplant 2012.
19. Loupy A, Lefaucheur C, Vernerey D, et al. Molecular Microscope Strategy to Improve Risk Stratification in Early Antibody-Mediated Kidney Allograft Rejection. J Am Soc Nephrol 2014.
20. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9 (8): 1826.
21. Lerut E, Naesens M, Kuypers DR, Vanrenterghem Y, Van Damme B. Subclinical peritubular capillaritis at 3 months is associated with chronic rejection at 1 year. Transplantation 2007; 83 (11): 1416.
22. Kokko KE, Colvin RB. Below the waterline -- the danger of de novo donor-specific HLA antibodies. Am J Transplant 2012; 12 (5): 1077.
23. Raghavaiah S, Stegall MD. New therapeutic approaches to antibody-mediated rejection in renal transplantation. Clin Pharmacol Ther 2011; 90 (2): 310.
24. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9 (11): 2129.
25. Hayde N, Broin P, Bao Y, et al. Increased intragraft rejection-associated gene transcripts in patients with donor-specific antibodies and normal biopsies. Kidney Int 2014; 86 (3): 600.
26. Danger R, Paul C, Giral M, et al. Expression of miR-142-5p in peripheral blood mononuclear cells from renal transplant patients with chronic antibody-mediated rejection. PLoS One 2013; 8 (4): e60702.
27. Iványi B, Fahmy H, Brown H, Szenohradszky P, Halloran PF, Solez K. Peritubular capillaries in chronic renal allograft rejection: a quantitative
21
334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373
ultrastructural study. Hum Pathol 2000; 31 (9): 1129.28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25 (4): 402.
22
374375376377
378
379
Table 1 Histological Findings
A) Biopsy diagnosis for de novo DSA patients (n=39 biopsies in n=30 patients)
Acute AbMR, C4d +, MI + (n=9) N=alone 2with features of chronic AbMR 5with features of chronic AbMR and TCMR 1with borderline TCMR 0with TCMR 1
Acute AbMR, C4d -, MI + (n=15)alone 4with features of chronic AbMR 4with features of chronic AbMR and TCMR 2with borderline TCMR 4with TCMR 1
C4d positive, no histological features of AbMR (n=2)Acute tubular injury 1BK, borderline TCMR 1
No AbMR (n=13)TCMR 1Acute tubular injury 5BK 2CNI toxicity 1Pyelonephritis 1Previously C4d- AbMR 1Diabetic GP 1Chronic vascular changes 1
Surveillance biopsies (n=18) were either within normal limits or had tubular injury/tubular
atrophy without histological features of rejection. All patients with biopsies in the de novo
DSA group had de novo DSA detected prior to the time of biopsy.
MI microcirculation inflammation; AbMR Antibody mediated rejection; TCMR T-cell mediated rejection; CNI calcineurin
inhibitor; Diabetic GP diabetic glomerulopathy; BK nephropathy
23
380
381
382
383384
385
386
387
388
389
b) Microcirculation inflammation
De novo DSA (n=39)
Surveillance (n=18)
PTC 0123
188
121
17100
G 0123
23664
18000
MI <11>1
156
18
1710
C4d 0123
161463
15300
Numbers of biopsies with each histological parameter
24
390391
392393
394
Table 2 Analysis of gene expression in different MI score groups
The de novo DSA only column shows the difference of transcript levels between MI0/1 and MI2+ only in group of patients with de novo DSA; de novo DSA and surveillance column shows difference of transcript levels between MI0/1 and MI2+ in the full group of biopsies; de novo DSA, C4d negative show only biopsies which have DSA but are C4d negative. Mann-Whitney U test MI ≤1v >1 has been used to generate significance p values.
Gene P-value (de novo DSA only, n=39)
P-value ( de novo DSA and Surveillance, n=57)
P-value (de novo DSA, C4d negative samples, n=30)
ENDATsCDH5 0.646 0.520 0.415DARC 0.606 0.012* 0.010*PECAM1 0.561 0.247 0.215SOX7 0.590 0.224 1.000vWF 0.281 0.071 0.112 NK Cell transcriptsCX3CR1 0.367 0.565 0.650FGFBP1 0.007* <0.001* 0.031*GNLY 0.001* <0.001* 0.001*KLRF1 0.073 0.002* 0.436MYBL1 0.010* 0.001* 0.003*SH2D1b 0.004* <0.001* 0.012*Inflammation transcripts
n=30+ n=44+
RPS6 0.126 0.262MALL 0.385 0.348TRIB1 0.486 0.274CXCL11 0.041* 0.007*RPS6KB1 0.395 0.147TNF 0.864 0.828PSMB8 0.673 0.940
*p≤0.05, +reduced numbers due to insufficient remaining RNA in some cases.
25
395
396397398399400
401
402
403
Table 3
a) Univariate binary logistic regression on all samples (n=57)
Parameter P- value Exp(B) 95% CI of Exp(B)
Lower Upper
ENDATsCDH5 0.369 2.165 0.401 11.689
DARC 0.05* 2.190 1.000 4.793
PECAM1 0.163 1.642 0.818 3.298
SOX7 0.193 0.505 0.181 1.414
vWF 0.086 1.965 0.910 4.244
NK Cell TranscriptsCX3CR1 0.156 1.644 0.828 3.265
FGFBP1 0.925 0.970 0.514 1.830
GNLY 0.002* 39.814 3.781 419.231
KLRF1 0.694 0.840 0.353 2.001
MYBL1 0.003* 7.323 2.006 26.737
SH2D1b 0.001* 6.083 2.021 18.313
Other parametersGender
(n=48)
0.547 1.571 0.361 6.842
Age at transplant
(n=48)
0.052 0.947 0.896 1.000
HLA mismatches
(n=48)
0.496 1.206 0.703 2.069
Donor age (n=48) 0.838 0.995 0.947 1.045
Live or deceased
donor (n=48)
0.404 1.789 0.456 7.021
Time from transplant
to biopsy
0.003* 1.749 1.209 2.532
26
404405
406
407
Expression of the 11 genes was assessed for correlation to MI score (≤1 or >1) in all 57
biopsies. Gender and age were also assessed but only in the first biopsy for each patient
(n=48).*p≤0.05
27
408
409
410
411
412
b) Univariate binary logistic regression on de novo DSA samples only (n=39)
Parameter P-value Exp(B) 95% CI of Exp(B)
Lower Upper
ENDATsCDH5 0.458 1.840 0.368 9.207
DARC 0.176 1.713 0.785 3.737
PECAM1 0.377 1.372 0.680 2.771
SOX7 0.212 0.628 0.303 1.302
vWF 0.272 1.518 0.721 3.199
NK Cell TranscriptsCX3CR1 0.162 1.915 0.771 4.756
FGFBP1 0.615 0.844 0.435 1.636
GNLY 0.012* 16.551 1.861 147.179
KLRF1 0.508 0.751 0.321 1.755
MYBL1 0.019* 4.586 1.278 16.456
SH2D1b 0.022* 3.927 1.219 12.658
Other parametersGender
(n=30)
0.706 1.333 0.298 5.957
Age at transplant
(n=30)
0.139 0.987 0.971 1.004
Time from transplant
to biopsy
0.313 1.105 0.910 1.342
Each of the 11 genes were assessed for correlation to MI score (≤1 or >1) in the de novo DSA
biopsies (n=39). Gender and age were assessed only in the first biopsy for each patient
(n=30).*p≤0.05
28
413
414
415
416
417
418419
Figure 1 Gene expression
Average Z-score for each gene is displayed according to MI group. Error bars represent the standard error of the mean (SEM). Surveillance n=18, de novo DSA MI 0-1 n= 21, de novo DSA MI 2-6 n= 18
Figure 2 Outcome Analysis
Patients were assigned to low or high risk groups depending on the transcript analysis. Survival from time of biopsy was plotted for all patients (a) or only patients with de novo DSA (b). Data was censored for patient death with functioning graft and short follow-up times.
Figure S1 Subgroup gene expressionGene expression for 11 genes from 39 de novo DSA and 18 surveillance samples divided according to AbMR status. The surveillance group (n=18) has reduced expression as previously shown. The majority of genes have increased expression in patients with active chronic AbMR. Patients with Acute AbMR appear to have a trend for reduced ENDAT expression but increased NK transcript expression.
29
420421
422423424425426427
428429430431
432433434435436437438439